Successful fertility management of a patient with factor V deficiency: planned transfusion of fresh frozen plasma under infertility treatment

2011 ◽  
Vol 95 (6) ◽  
pp. 2124.e5-2124.e7 ◽  
Author(s):  
Akira Iwase ◽  
Maki Goto ◽  
Shuichi Manabe ◽  
Wakana Hirokawa ◽  
Hiroharu Kobayashi ◽  
...  
1976 ◽  
Vol 7 (5) ◽  
pp. 400-405
Author(s):  
Hiroshi INABA ◽  
Yasumasa SUGA ◽  
Osamu TATSUZAWA ◽  
Masatoshi KOSAKI ◽  
Toshio SEKIMOTO ◽  
...  

1965 ◽  
Vol 14 (01/02) ◽  
pp. 074-082 ◽  
Author(s):  
B Rush ◽  
H Ellis

SummaryTwo patients with congenital factor-V deficiency and a third with a combined deficiency of factor V and factor VIII are described. Under cover of fresh frozen plasma, tooth extractions were performed on two of these patients and spontaneous bleeding arrested.It is concluded that the achievement of a blood level of factor V of 20 per cent once daily is sufficient to assure adequate haemostasis. A low recovery of factor V activity in the plasma following infusion was found. However, in spite of this, adequate blood levels were easily attained due to the excellent preservation of factor V activity in the stored fresh frozen plasma.


2020 ◽  
Vol 42 ◽  
pp. 404-405
Author(s):  
C.M. Wink ◽  
J.S. Palaoro ◽  
D. Glimm ◽  
A.A.C. Araujo ◽  
C.S.R. Araujo

Blood ◽  
1980 ◽  
Vol 56 (4) ◽  
pp. 585-595 ◽  
Author(s):  
DK Hasegawa ◽  
AJ Bennett ◽  
PF Coccia ◽  
NK Ramsay ◽  
ME Nesbit ◽  
...  

Abstract Factor V deficiency has been identified in 8 of 8 patients 7--20 yr of age, with Philadelphia-positive (Ph1+) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%--12% (0.10--0.12 U/ml) after the infusion of 28--31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph1+ CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20--80 yr, with Ph1+ CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid- megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders.


2020 ◽  
Vol 65 (3) ◽  
pp. 351-359
Author(s):  
G. M. Galstyan ◽  
T. V. Gaponova ◽  
F. S. Sherstnev ◽  
A. A. Kupryashov ◽  
N. I. Olovnikova ◽  
...  

Introduction. Cryosupernatant is blood component. Cryosupernatant is the supernatant plasma removed during the preparation of cryoprecipitate. Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of Cryosupernatant. General fi ndings. In comparison with fresh frozen plasma (FFP) and cryoprecipitate, Cryosupernatant plasma is depleted in factor VIII, fi brinogen factor von Willebrand (VWF). Cryosupernatant is defi cient in high molecular weight multimers of VWF, but contains VWF metalloproteinase. The concentrations of factor V, antithrombin III, albumin and immunoglobulins are the same as in FFP and cryoprecipitate. The indications for Cryosupernatant transfusions are massive blood loss in patients with factor VIII inhibitor, plasma exchange in patients with thrombotic thrombocytopenic purpura. For children the doses of Cryosupernatant should be 10-15 mL/kg.


2004 ◽  
Vol 15 (8) ◽  
pp. 699-700
Author(s):  
Catherine Boinot ◽  
Laurent Macchi ◽  
Maryse Guicheteau ◽  
Louis E Gayet ◽  
Martine Aperc?? ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document